Life Biosciences’ new fundraising push seeks answers to big aging questions, but won’t be drawn on its strategy.
Harvard scientist David Sinclair is one of Longevity’s big hitters. Just a year after raising $50M in Series B financing, his company Life Biosciences LLC is looking for $100M to progress its anti-aging research .
Longevity.Technology: Life Biosciences had an original Series B goal of $25M; it doubled it. As NAD continues to embed in the anti-aging supplement marketplace, the company is looking to expand, with a range of subsidiaries under its Longevity umbrella. Although the company isn’t spilling any secrets on its proposed clinical trials, we will be sure to keep a close eye on progress.
Life Biosciences, valued last year at approximately $500M, is built on Sinclair’s experience as co-Director of the Paul F Glenn Center for the Biology of Aging at Harvard Medical School, as a genetics professor at Harvard University and on previously-founded companies Arc Bio, Genocea and Ovascience.
Life Biosciences has been researching nicotinamide adenine dinucleotide (NAD) and its precursor, nicotinamide mononucleotide (NMN), for some time. NAD is a key regulator of protein-to-protein interactions in DNA repair and a controller of cell-damaging oxidation and NMN is a NAD-booster. David makes no secret that he takes NMN regularly .
Life Biosciences is also investigating the molecular pathways behind aging and age-related diseases through a range of subsidiary companies that include Jumpstart Fertility, Senolytx and Continuum Biosciences.
These expansions have allowed Life Biosciences to push into researching AI platforms, robotics, senotherapeutic drug discovery, cellular reprogramming and fertility restoration.
The latest funding push, $100M according to documents filed with the US Securities and Exchange Commission (SEC), could well see some important clinical trials getting underway. Watch this space!
Image courtesy of Life Biosciences